Vir Biotechnology, Inc. cotiza a 11.30 USD y tiene una capitalización bursátil de $1.9B. En los últimos 12 meses ha facturado $303M con un margen de flujo de caja libre del -578.5%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $0.47 | $-0.85 | $-0.31 |
| Estimado | $-0.73 | $0.90 | $0.48 | $-0.45 |
| Sorpresa | — | -47.8% | -277.1% | +31.1% |
| Métrica | VIR | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 100.0% | 57.0% | +42.9% |
| Operating Margin | -699.2% | -38.6% | -660.6% |
| Net Margin | -638.9% | -33.6% | -605.3% |
| FCF Margin | -578.5% | -13.9% | -564.7% |
| ROE | -57.2% | -40.4% | -16.8% |
| ROA | -43.7% | -32.0% | -11.7% |
| Current Ratio | 5.54 | 2.84 | +2.70 |
| Debt / Equity | — | 0.28 | — |